AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Signaling Through the Extracellular Calcium-Sensing Receptor (CaSR)2012
- Update on Bone Anabolics in Osteoporosis Treatment: Rationale, Current Status, and PerspectivesThe Journal of Clinical Endocrinology & Metabolism, 2012
- ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humansBone, 2011
- Calcilytics: Antagonists of the Calcium-Sensing Receptor for the Treatment of OsteoporosisFuture Medicinal Chemistry, 2011
- An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formationBone, 2010
- Rapid and robust response of biochemical markers of bone formation to teriparatide therapyBone, 2009
- Quality-of-life issues in osteoporosisCurrent Rheumatology Reports, 2005
- Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2001
- Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1–84)] in healthy postmenopausal volunteers*Clinical Pharmacology & Therapeutics, 1997
- ANABOLIC EFFECT OF LOW DOSES OF A FRAGMENT OF HUMAN PARATHYROID HORMONE ON THE SKELETON IN POSTMENOPAUSAL OSTEOPOROSISThe Lancet, 1976